We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+32.6%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$9.65B
AUM Growth
+$1.82B
Cap. Flow
+$94.6M
Cap. Flow %
0.98%
Top 10 Hldgs %
77.89%
Holding
99
New
5
Increased
16
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$62M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$37.7M
3
IMVT icon
Immunovant
IMVT
+$22.4M
4
BCAX
Bicara Therapeutics
BCAX
+$21.3M
5
SMMT icon
Summit Therapeutics
SMMT
+$16.8M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$28M
2
LONA
LeonaBio Inc
LONA
+$8.36M
3
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$4.4M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$2.28M
5
SAGE
Sage Therapeutics
SAGE
+$1.86M

Sector Composition

Rank Sector Weight
1 Healthcare 98.95%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
76
Enliven Therapeutics
ELVN
$4.38B
$2.93M 0.03%
114,833
– –
CMPX icon
77
Compass Therapeutics
CMPX
$432M
$2.87M 0.03%
1,557,630
– –
WVE icon
78
Wave Life Sciences
WVE
$1.04B
$2.82M 0.03%
+344,063
New +$2.06M
MRSN
79
DELISTED
Mersana Therapeutics
MRSN
$2.05M 0.02%
43,445
– –
NAMS icon
80
NewAmsterdam Pharma
NAMS
$3.33B
$1.61M 0.02%
96,711
-116
-0.1% -$2.01K
IPSC icon
81
Century Therapeutics
IPSC
$375M
$1.36M 0.01%
797,460
– –
VTVT icon
82
vTv Therapeutics
VTVT
$132M
$1.32M 0.01%
97,314
– –
JBIO
83
Jade Biosciences
JBIO
$1.36B
$1.31M 0.01%
17,970
– –
PFE icon
84
Pfizer
PFE
$160B
$1.01M 0.01%
35,000
– –
TARA icon
85
Protara Therapeutics
TARA
$228M
$982K 0.01%
536,832
– –
ALGS icon
86
Aligos Therapeutics
ALGS
$41.7M
$719K 0.01%
83,055
-1
-0% -$12
BCRX icon
87
BioCryst Pharmaceuticals
BCRX
$2.44B
$576K 0.01%
75,778
– –
PMVP icon
88
PMV Pharmaceuticals
PMVP
$71.1M
$480K 0.01%
322,024
– –
FHTX icon
89
Foghorn Therapeutics
FHTX
$420M
$419K ﹤0.01%
45,027
– –
ACRV icon
90
Acrivon Therapeutics
ACRV
$94.7M
$370K ﹤0.01%
52,885
– –
TYRA icon
91
Tyra Biosciences
TYRA
$1.55B
$249K ﹤0.01%
10,607
– –
SRZNW
92
DELISTED
Surrozen Inc Warrant
SRZNW
$8.58K ﹤0.01%
833,333
– –
ADAP
93
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-2,343,695
Closed -$2.28M
LONA
94
LeonaBio Inc
LONA
$72.4M
– –
-315,381
Closed -$8.36M
SAGE
95
DELISTED
Sage Therapeutics
SAGE
– –
-171,026
Closed -$1.86M
ACHL
96
DELISTED
Achilles Therapeutics
ACHL
– –
-1,108,767
Closed -$904K
TLIS
97
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
– –
-508,323
Closed -$4.4M
CERE
98
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-683,588
Closed -$28M
1 2 3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2024 Portfolio in Review

As of Q3 2024, Julian Baker held 99 positions worth $9.65B, up 23% from $7.83B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Julian Baker's Q3 2024 filing shows 5 new, 16 increased, 3 reduced and 6 closed positions. Its largest new stake was Bicara Therapeutics: 833,333 shares worth $21.2M. The largest sale was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $28M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2024 buy was Bicara Therapeutics: 833,333 shares worth $21.2M.
  • Julian Baker added most to Insmed in Q3 2024, an estimated $62M increase.
  • Julian Baker's biggest Q3 2024 reduction was NewAmsterdam Pharma, cutting an estimated $2.01K.
  • Julian Baker fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $28M.
  • Julian Baker's ten largest holdings make up 78% of its $9.65B portfolio in Q3 2024.
  • Julian Baker opened 5 new positions and closed 6 in Q3 2024.
  • Julian Baker's portfolio value rose 23% quarter-over-quarter to $9.65B.

Based on Baker Bros. Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.